Approval · Notice of Compliance 13896 · 2012
PMS-OXYCODONE CR: Notice of Compliance 13896
Issued November 26, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13896
- Date
- November 26, 2012
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- New strengths
- Therapeutic class
- Opioid analgesic
- Canadian reference product
- OXYCONTIN (Purdue Pharma)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PMS-OXYCODONE CR | 02397544 | Cancelled Pre Market |
| PMS-OXYCODONE CR | 02397552 | Cancelled Pre Market |
| PMS-OXYCODONE CR | 02397560 | Cancelled Pre Market |
Medicinal ingredients
- OXYCODONE HYDROCHLORIDE 15 MG per TAB
- OXYCODONE HYDROCHLORIDE 30 MG per TAB
- OXYCODONE HYDROCHLORIDE 60 MG per TAB